PDF(Pubmed)
Abstract：
BACKGROUND: Accumulating evidence suggests that the inflammatory cytokine interleukin-6 (IL-6) contributes to the pathophysiology of psychiatric disorders. However, there was no study concerning the relationship between IL-6 concentrations and clinical features in the chronic phase of early-onset schizophrenia (EOS).
OBJECTIVE: To investigate the relationship between serum IL-6 concentration and the clinical features of EOS.
METHODS: We measured serum IL-6 Levels from 74 patients with chronic schizophrenia, including 33 with age at onset < 21 years (EOS group) and 41 with onset ≥ 21 years in [adult-onset schizophrenia (AOS) group], and from 41 healthy controls. Symptom severities were evaluated using the Positive and Negative Syndrome Scale (PANSS).
RESULTS: Serum IL-6 concentrations were higher in both EOS and AOS groups than healthy controls (F = 22.32, P < 0.01), but did not differ significantly between EOS and AOS groups (P > 0.05) after controlling for age, body mass index, and other covariates. Negative symptom scores were higher in the EOS group than the AOS group (F = 6.199, P = 0.015). Serum IL-6 concentrations in the EOS group were negatively correlated with both total PANSS-negative symptom score (r = -0.389, P = 0.032) and avolition/asociality subscore (r = -0.387, P = 0.026).
CONCLUSIONS: Patients with EOS may have more severe negative symptoms than those with adult-onset schizophrenia during the chronic phase of the illness. IL-6 signaling may regulate negative symptoms and its avolition/asociality subsymptoms among the early-onset chronic schizophrenic patients.
OBJECTIVE: To investigate the relationship between serum IL-6 concentration and the clinical features of EOS.
METHODS: We measured serum IL-6 Levels from 74 patients with chronic schizophrenia, including 33 with age at onset < 21 years (EOS group) and 41 with onset ≥ 21 years in [adult-onset schizophrenia (AOS) group], and from 41 healthy controls. Symptom severities were evaluated using the Positive and Negative Syndrome Scale (PANSS).
RESULTS: Serum IL-6 concentrations were higher in both EOS and AOS groups than healthy controls (F = 22.32, P < 0.01), but did not differ significantly between EOS and AOS groups (P > 0.05) after controlling for age, body mass index, and other covariates. Negative symptom scores were higher in the EOS group than the AOS group (F = 6.199, P = 0.015). Serum IL-6 concentrations in the EOS group were negatively correlated with both total PANSS-negative symptom score (r = -0.389, P = 0.032) and avolition/asociality subscore (r = -0.387, P = 0.026).
CONCLUSIONS: Patients with EOS may have more severe negative symptoms than those with adult-onset schizophrenia during the chronic phase of the illness. IL-6 signaling may regulate negative symptoms and its avolition/asociality subsymptoms among the early-onset chronic schizophrenic patients.
摘要：
背景：越来越多的证据表明，炎性细胞因子白细胞介素-6（IL-6）有助于精神疾病的病理生理学。然而,没有关于早发性精神分裂症(EOS)慢性期IL-6浓度与临床特征之间关系的研究.
目的：探讨血清IL-6浓度与EOS临床特征的关系。
方法：我们测量了74例慢性精神分裂症患者的血清IL-6水平，包括发病年龄<21岁的33人（EOS组）和[成年精神分裂症（AOS）组]发病年龄≥21岁的41人，和41个健康对照。使用阳性和阴性综合征量表（PANSS）评估症状严重程度。
结果：EOS组和AOS组的血清IL-6浓度均高于健康对照组（F=22.32，P<0.01），但在控制年龄后，EOS和AOS组之间没有显着差异（P>0.05），身体质量指数,和其他协变量。EOS组阴性症状评分高于AOS组(F=6.199,P=0.015)。EOS组血清IL-6浓度与PANSS阴性症状总评分（r=-0.389，P=0.032）和自主/自我意识子评分（r=-0.387，P=0.026）均呈负相关。
结论：在疾病的慢性期，EOS患者可能比成年精神分裂症患者有更严重的阴性症状。IL-6信号传导可能调节早发性慢性精神分裂症患者的阴性症状及其空/性亚症状。
目的：探讨血清IL-6浓度与EOS临床特征的关系。
方法：我们测量了74例慢性精神分裂症患者的血清IL-6水平，包括发病年龄<21岁的33人（EOS组）和[成年精神分裂症（AOS）组]发病年龄≥21岁的41人，和41个健康对照。使用阳性和阴性综合征量表（PANSS）评估症状严重程度。
结果：EOS组和AOS组的血清IL-6浓度均高于健康对照组（F=22.32，P<0.01），但在控制年龄后，EOS和AOS组之间没有显着差异（P>0.05），身体质量指数,和其他协变量。EOS组阴性症状评分高于AOS组(F=6.199,P=0.015)。EOS组血清IL-6浓度与PANSS阴性症状总评分（r=-0.389，P=0.032）和自主/自我意识子评分（r=-0.387，P=0.026）均呈负相关。
结论：在疾病的慢性期，EOS患者可能比成年精神分裂症患者有更严重的阴性症状。IL-6信号传导可能调节早发性慢性精神分裂症患者的阴性症状及其空/性亚症状。
